Ikaria, a Clinton, N.J.-based biopharma company, has filed for a $200 million IPO. It plans to trade on the Nasdaq under ticker symbol IKAR, with Goldman Sachs and Morgan Stanley serving as co-lead underwriters.
The company reports nearly $275 million in 2009 revenue, compared to $237 million last year. Its net income grew from $9.6 million to $13 million.
Ikaria shareholders include New Mountain Capital (50.98% pre-IPO position), Linde (17.1%), ARCH Venture Partners (10.13%), Venrock (10.1%), 5AM Ventures, Alexandria Equities, Altitude Life Science Ventures and Washington Research Foundation. New Mountain and Linde joined in 2007, when New Mountain invested $200 million to fund Ikaria’s $670 million acquisition of gaseous drugmaker INO Therapeutics from Linde. www.ikariainc.com
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.